Cellectis Posts $188 Million Cash, Cema-cel Delivers 58.3% MRD Negativity
CLLS•Cellectis held $188 million in cash at March 31, 2026, funding operations into Q4 2027, and its ALPHA3 trial of cema-cel showed 58.3% MRD negativity versus 16.7% with no serious treatment-related events. Interim analysis of lasme-cel Phase 2 and full eti-cel Phase 1 data both arrive in Q4 2026.
1. Q1 2026 Financial Position
As of March 31, 2026, Cellectis reported cash, cash equivalents and fixed-term deposits totaling $188 million, including $150.6 million in fixed-term deposits and $2.3 million of restricted cash, providing operating runway into Q4 2027.
2. ALPHA3 Interim Data
Interim results from the ALPHA3 trial of cema-cel showed 58.3% of patients achieved MRD negativity compared to 16.7% in the observation arm, with no cases of cytokine release syndrome, neurotoxicity, graft-versus-host disease or treatment-related serious adverse events.
3. Upcoming Clinical Milestones
Cellectis expects pivotal Phase 2 first interim analysis for lasme-cel in relapsed or refractory B-ALL and full Phase 1 dataset for eti-cel in relapsed or refractory NHL both in Q4 2026, and plans a Biologics License Application submission in 2028.
4. Preclinical Innovation and Collaborations
The company’s TALE-based epigenetic editing platform achieved over 90% stable gene silencing across two targets without DNA cuts, and partnerships with AstraZeneca and Servier (via Allogene) support development of up to 10 novel cell and gene therapies.
